Psoriasis severity was not affected by vitamin D supplementation, according to a study published in
JAMA Dermatology. Marita Jenssen, MD, and colleagues conducted a randomized, placebo-controlled,
double-blind clinical trial with two parallel groups through two winters. Adults from the general
population with active plaque psoriasis and 25-hydroxyvitamin D (25[OH]D) levels of less than 24
ng/mL were included (N=122); 120 participants completed the study. For 4 months, participants were
administered vitamin D (cholecalciferol, 100,000 IU, loading dose, followed by 20.000 IU/week) or
placebo. No significant difference in change in PASI score between the groups was observed
(adjusted difference, 0.11; 95% CI, -0.23 to 0.45). Likewise, there was no notable difference in
change in Dermatology Life Quality Index (ad- justed difference, -0.86; 95% CI, -1.9 to 0.19),
Physician Global Assessment score (adjusted OR, 0.66; 95% CI, 0.27-1.63), self-administered PASI
(adjusted difference, -0.60; 95% CI, -1.76 to 0.55) or between the groups.
